<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Among the side-effects of cetuximab hypomagnesaemia has been described, but the information is still limited </plain></SENT>
<SENT sid="2" pm="."><plain>METHODOLOGY: We have evaluated retrospectively serum <z:chebi fb="131" ids="25107">magnesium</z:chebi>, <z:chebi fb="120" ids="26216">potassium</z:chebi>, calcium, <z:chebi fb="0" ids="16737">creatinine</z:chebi> and albumin in 51 consecutive patients with metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> treated with cetuximab, mostly combined with irinotecan-based combination chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A significant decrease of serum <z:chebi fb="131" ids="25107">magnesium</z:chebi>, <z:chebi fb="120" ids="26216">potassium</z:chebi>, calcium and corrected serum calcium, <z:chebi fb="0" ids="16737">creatinine</z:chebi> and albumin concentrations was already evident one week after the start of treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Hypomagnesaemia of any grade was detected in 56% of evaluable patients, but grade 3 or grade 4 hypomagnesaemia was observed in 6% and 4% of patients, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Grade 1 <z:hpo ids='HP_0002900'>hypokalemia</z:hpo> was detected in 47%, grade 3 in 17% and grade 4 <z:hpo ids='HP_0002900'>hypokalemia</z:hpo> was detected in 6% of the patients </plain></SENT>
<SENT sid="6" pm="."><plain>Among evaluable patients grade 1 <z:hpo ids='HP_0002901'>hypocalcaemia</z:hpo> was detected in (36%), grade 2 <z:hpo ids='HP_0002901'>hypocalcaemia</z:hpo> in 42%, grade 3 in 4% and grade 4 in 13% of patients </plain></SENT>
<SENT sid="7" pm="."><plain>Baseline <z:hpo ids='HP_0002901'>hypocalcaemia</z:hpo> of grade 1 or higher was associated with significantly inferior survival </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Asymptomatic hypomagnesaemia, <z:hpo ids='HP_0002900'>hypokalemia</z:hpo> and <z:hpo ids='HP_0002901'>hypocalcaemia</z:hpo> are common in metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> patients treated with cetuximab </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0002901'>Hypocalcaemia</z:hpo> is a predictor of poor prognosis </plain></SENT>
</text></document>